Trevena’s Maxine Gowen named CEO of the Year by PA Bio
PA Bio recognizes Gowen’s leadership and commitment to patients
KING OF PRUSSIA, Pa.--(BUSINESS WIRE)-- Yesterday, Pennsylvania Bio, the statewide life sciences industry trade association, announced that Maxine Gowen, Ph.D., president and chief executive officer of Trevena, Inc., has won the prestigious 2013 Frank Baldino Jr. CEO of the Year Award. Dr. Gowen will be honored at PA Bio’s Annual Dinner and Awards Celebration and Ceremony on March 13th in Philadelphia.
The Baldino Award recognizes a CEO who has shown visionary leadership, exceptional achievement and unerring commitment to patients and the industry. “Maxine epitomizes the life sciences entrepreneur of today,” said Christopher Molineux, PA Bio’s President. “She embodies the definition of the award she is receiving.”
“It is a true honor to be selected for this award and to be connected to Frank Baldino’s tremendous legacy,” said Dr. Gowen. “I would like to recognize the superb team at Trevena, who are working tirelessly to bring biased GPCR ligands to the clinic as better medicines. It’s that passion for better health which drives our entire industry forward.”
Dr. Gowen has been successful in her career as both a scientist and as a business leader. Prior to joining Trevena as the founding CEO in 2007, Dr. Gowen held a variety of leadership roles at GlaxoSmithKline (GSK) over a period of 15 years. She was senior vice president for external drug discovery, president and managing partner at SR One, the venture capital subsidiary of GSK, and held various roles in drug discovery. She has authored more than 100 refereed scientific publications. Dr. Gowen has received degrees from the University of Bristol, UK, the University of Sheffield, UK, and the Wharton School of the University of Pennsylvania. Dr. Gowen is currently serving on the Board of Directors of the Biotechnology Industry Association, and chairs an advisory board at GSK.
In 2012 Trevena successfully completed two mid-stage trials on its first-in-class heart failure compound TRV027, and a first in human study on TRV130 in development for post-operative pain. Both compounds were derived from Trevena’s novel biased ligand platform technology.
About Trevena and Biased Ligands
Trevena, Inc. is a clinical stage pharmaceutical company focused on discovering and developing the next generation of G-protein coupled receptor (GPCR) targeted medicines. GPCRs are the targets for at least one-third of modern medicinal products, and remain the predominant class of targets under clinical evaluation. Trevena’s expertise lies in engineering “biased ligands” that activate only the beneficial signaling pathways downstream of a GPCR to unlock new biology and avoid drug adverse effects. Trevena’s pipeline currently includes TRV027, a Phase 2 clinical stage angiotensin receptor biased ligand for acute heart failure, TRV130, a Phase 1 clinical mu-opioid biased ligand for post-operative pain, and discovery-stage programs for chronic pain and Parkinson’s disease. Trevena is based in King of Prussia, Pennsylvania and is backed by leading investors including Alta Partners, Healthcare Ventures, NEA, Polaris and Yasuda Enterprise Development Company. For more information about the company, please visit www.trevenainc.com.
Media Contact:
Trevena, Inc.
Alastair Southwell,
610-354-8840
asouthwell@trevenainc.com
or
Investor
Contact:
Trevena, Inc.
Ros Deegan, 610-354-8840
rdeegan@trevenainc.com
Source: Trevena, Inc.
Released February 8, 2013